thought call
follow solid beat rais ingrezza sale
increas tp maintain outperform
rate believ ingrezza much room grow
compani expand promot effort like drive continu penetr
address td market estim patient
us current penetr per estim encourag
growth patient start modestli increas ingrezza estim
throughout forecast could see rel weak due
season expect contract increas expect sale ingrezza
reach sinc initi launch ingrezza outperform
sale expect everi quarter quarter believ continu
execut ingrezza could drive upsid sharesnow
season impact potenti contract better appreci
estim strong base busi interest pipelin option
maintain neurocrin top-pick small mid-cap biotech sector
earli stage pipelin still well reflect current share price overal
continu believ current valuat share underestim
market penetr potenti best-in-class ingrezza increment upsid
orilissa approv uterin fibroid opicapon larg market
signific unmet need also believ current share price
fulli reflect addit opportun congenit adren hyperplasia
recent gene therapi program reiter outperform rate increas
tp
valuat risk valu share use sum-of-the-part sotp
dcf analysi assum wacc tvgr result tp
increas ep improv outlook
fda/ema approv product commerci ingrezza orilissa
sell well predict price market risk
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
inc commercial-stag
biopharmaceut compani discov develop intend
commerci drug treatment neurolog endocrin
relat diseas disord
price jul rate outperform target price analyst evan seigerman
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
blue sky valuat base fda approv
elagolix uterin fibroid opicapon parkinson diseas
also assum posit pivot congenit adren
hyperplasia posit data gene therapi asset vy-aadc
voyag transact furthermor
assum better expect growth ingrezza orilissa
grey sky valuat assum fda approv
elagolix uterin fibroid opicapon parkinson diseas
assum neg top-line pivot congenit
adren hyperplasia grey sky also assum lower expect
revenu ingrezza orilissa endometriosi
pipelin updat fda accept nda opicapon pdufa per
neurocrin compani expect begin pivot studi congenit adren
hyperplasia pend fda discuss
model adjust increas ingrezza estim
base better-than-expect sale construct ingrezza given
compani enhanc promot effort increas market penetr given
lower-than-expect sale orilissa lower near-term expect
royalti launch orilissa slower
anticip continu believ better long-term growth achiev
potenti approv uterin fibroid lower sg
base compani guidanc updat quarter on-going sg expens
exclud ipr expect approxim million
million million result forecast non-gaap ep
figur
figur neurocrin quarterli annual ep usd
profit loss tax
cog revenu
 revenu
sg revenu
valuat price target per share base sum-of-the-part dcf
analysi assum discount rate fulli dilut share tax rate
lower discount rate believ lower discount rate
reflect decreas risk associ research develop focus
biotechnolog compani move earli stage commerci
predict sustain growth assign termin growth free cash flow
assum neurocrin small molecul asset retain signific valu beyond
patent expir commerci exclus yet believ compani on-going
invest success replac revenu long-
sotp analysi base sotp dcf primarili driven valuat sale
ingrezza td quarter increas expect ingrezza
base better-than-expect revenu valu opicapon risk adjust
royalti orilissa endometriosi valu po
lower expect orilissa given lower-than-expect top-line revenu
report partner royalti neurocrin royalti uterin
fibroid indic risk adjust valu program
valu risk adjust combin unalloc corpor
expens net cash sotp dcf valu neurocrin
compani mention price
